Generation Bio Closes $100M Series B Round for Re-dosable Gene Therapy Candidate

March 2, 2018: By Joan McKenna

Generation Bio announced Feb. 27 that it closed a $100 million Series B financing to advance its GeneWave platform for re-dosable gene therapy.

The Cambridge, Massachusetts, company, founded in 2016, is focused on creating gene therapies that deliver durable, high levels of gene expression and can be re-dosed to titrate and sustain effect.

Generation Bio’s platform is based on a method of non-viral gene transfer, known as closed-ended DNA, or ceDNA.

GeneWave uses a lipid nanoparticle to deliver ceDNA to tissues.

The company said the round will be used to fund studies for its lead candidates in liver disease and to support the development of approaches to deliver ceDNA to other tissues, such as the eye, to treat genetic retinal disorders.

The financing was led by Fidelity Management & Research Company, with participation by Invus, Deerfield Management Company, Casdin Capital, Foresite Capital, and Leerink Partners’ Affiliates.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales